Search Results - clinical+and+disease+specializations+%3e+oncology+%3e+liver+cancer

6 Results

Sort By:

A DNAJB1-PRKACA fusion kinase peptide vaccine for patients with fibrolamellar hepatocellular carcinoma

Unmet NeedFibrolamellar carcinoma (FLC) is an extremely rare form of cancer. It affects both men and women in approximately 1 in 5,000,000 people with greater frequency among young adults with a median age of diagnosis of 25. Unfortunately, there is no standard of care therapy for this cancer, and patients with this disease have an expected median survival...

Published: 3/14/2025 | Inventor(s): Mark Yarchoan, Elizabeth Jaffee, Aditya Mohan

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities > Immunotherapies

Locoregional Chemotherapy for Liver Cancers

Unmet NeedOver 800,000 people are diagnosed with liver cancer annually. As the leading cause of cancer death worldwide, liver cancer accounts for more than 700,000 deaths annually. Recently, Johns Hopkins researchers have developed new chemotherapeutic drugs to treat liver cancer that demonstrate higher efficacy than the current standard of care for...

Published: 3/14/2025 | Inventor(s): Florin Selaru, Ling Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Mechanism, Liver Cancer, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Liver Cancer

Alpha particle formulations for treatment of solid tumors

Unmet NeedHepatocellular carcinoma (HCC) is the fifth most common cancer type worldwide and a leading cause of cancer related deaths. HCC is clinically silent in its early stages, leading to diagnosis at more advanced stages when only non-surgical, palliative treatment is available. One treatment option for advanced HCC is intra-arterial therapy and...

Published: 3/14/2025 | Inventor(s): Jessie Nedrow, Eleni Liapi

Keywords(s): Biologics, Cancers, Disease Indication, Liver Cancer, Non-novel, Predicted Novelty, Radioisotope Therapy, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

MicroRNA Delivery as a Novel Therapeutic Strategy for Liver Cancer

Unmet needOver 500,000 people are diagnosed with liver cancer worldwide each year. According the American Cancer Society, liver cancer resists most chemotherapy drugs and the most effective agents shrink less than 1 in 5 tumors and generally for only a short time. Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage making it difficult...

Published: 3/13/2025 | Inventor(s): Kathryn Mendell, Raghu Chivukula, Janaiah Kota, Erik Wentzel, Jerry Mendell, K. Clark, Joshua Mendell

Keywords(s): Biologics, Cancers, Disease Indication, Gene Therapy, Liver Cancer, Nucleic Acid, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Liver Cancer

scAAV.EF1a.miR26a.eGFP Plasmid

C10912: A plasmid to produce recombinant adeno-associated virus (AAV) that expresses microRNA-26a and green fluorescent proteinValue Proposition: • miR-26a, cloned into the short intron that is part of the EF1a promoter unit, thus allowing simultaneous production of eGFP and miR-26a from a single transcript • efficient expression of both...

Published: 3/13/2025 | Inventor(s): Erik Wentzel, K. Clark, Janaiah Kota, Jerry Mendell, Kathryn Mendell, Raghu Chivukula, Joshua Mendell

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Gene Therapy, Liver Cancer, Plasmid/Vector, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology, Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Research Tools > Vectors & Plasmids

Microenvironment-informed combinatorial therapy for hepatocellular carcinoma

Unmet NeedSorafenib, a kinase inhibitor, has been the gold-standard treatment for most individuals with hepatocellular carcinoma (HCC); however, studies suggest survival after treatment remains less than 15% (Raoul et al. 2019). Additionally, side effects, including hand-foot skin reactions and diarrhea, are prevalent in almost half of patients being...

Published: 3/13/2025 | Inventor(s): Ming Hsu, Jih-Ru Hwu, Szu Wu, David Mold, Ru Chih Huang

Keywords(s): Cancers, Disease Indication, Liver Cancer, Therapeutic Matter, Therapeutics